Inclusion Criteria:

• Cisgender women assigned female at birth
• Age 18 years or older
• Stage 1-3 hormone receptor-positive breast cancer
  • Premenopausal patients being treated with GNRH agonist/antagonist to induce menopause are eligible
  • Patients who received treatment with CDK 4/6 inhibitors are eligible
• Recommended to continue AET for ≥2 additional years after enrollment
• Low adherence defined as prescription fills with a proportion of days covered (PDC) of <80%, examined over all fills during the 2 years prior to date of eligibility review since the first AET prescription/data of AET start OR unable to calculate adherence
• Verbal fluency in English or Spanish
• Ability to understand informed consent and the willingness to sign it

Exclusion Criteria:

• Unable to verbalize comprehension of study or impaired decision-making
• Known distant metastatic disease
• Evidence that an oncology provider discontinued their AET
• Pregnant or trying to get pregnant
• Facility-administered medications (i.e., nursing home, home healthcare agency)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 09/26/2024. Questions regarding updates should be directed to the study team contact.